Opthea Ltd. ADR (OPT) News
Filter OPT News Items
OPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OPT News Highlights
- For OPT, its 30 day story count is now at 2.
- Over the past 8 days, the trend for OPT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about OPT are AMD and DEC.
Latest OPT News From Around the Web
Below are the latest news stories about OPTHEA LTD that investors may wish to consider to help them evaluate OPT as an investment opportunity.
Opthea to Receive US$35M Commitment and Additional US$50M FundingOpthea to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and its life science franchise Abingworth, as well as a further US$50m financing under an Amended DFA to include a new co-investor This financing is non-dilutive to shareholders, with no equity issued to Carlyle, Abingworth or the new co-investor Investment driven by the potential of sozinibercept (OPT-302) to provide superior visual outcomes for wet AMD patients and to provide a multi-billion d |
Opthea Receives A$8.8 million R&D Tax IncentiveMELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.8 million (US$5.9 million) research and development (R&D) tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2022/2023 financial year, and represents the amount d |
Opthea to Present at the FLORetina 2023 CongressMELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy. Professor Angelo Maria Minnella, MD from the Department of Ophthalmology, Catholic Unive |
Opthea to Present at the Jefferies 2023 London Healthcare ConferenceMELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Founder and Chief Innovation Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference being held on November 14th -16th, 2023. Dr. Baldwin’s fireside chat with Jefferies Analyst, Kelly Shi |
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) ConferenceMELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Founder & Chief Innovation Officer, will present at Eyecelerator which is part of AAO 2023 being held in San Francisco, CA on November 3rd to 6th, 2023. Dr. Baldwin will present on Thursday, November 2nd at 1:36pm PST as p |
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFODr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors Experienced pharmaceutical executives Dr. Frederic Guerard appointed as CEO and Peter Lang appointed as CFO, bringing complementary expertise to lead Opthea’s next phase of growth MELBOURNE, Australia, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal d |
Opthea Limited (ASX:OPT) is definitely on the radar of institutional investors who own 38% of the companyKey Insights Significantly high institutional ownership implies Opthea's stock price is sensitive to their trading... |
Opthea to Participate at the 2023 Euretina CongressMELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that on October 4th, Dr. Megan Baldwin, the Company’s Chief Executive Officer will be a panelist at the inaugural Euretina Innovation Spotlight forum which is part of the Organization’s 23rd Congress being held on October 5th – 8th in Amsterdam, The Netherland |
10 Best ASX Stocks To Invest InIn this article, we take a look at the 10 best ASX stocks to invest in. If you want to see more stocks listed on the ASX, go directly to the 5 Best ASX Stocks To Invest In. Australia, formally known as the Commonwealth of Australia, is an independent nation encompassing the primary landmass of […] |
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceMELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company’s Chief Financial Officer will present at H.C. Wainwright’s 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th – 13th, 2023. Mr. Morris will present on Wed |